


PERSONALIZED MEDICINE IN WOMEN CANCER



Dr. Jeremie Arash Rafii Tabrizi

**Associate Professor of Genetic Medicine and
Obstetrics and Gynecology,
Weill Cornell Medicine - Qatar**

Sunday April 8, 2018

3:30 PM – 4:30 PM

Lecture Hall 3

Target Audience:

Professionals across the healthcare spectrum including physicians, pharmacists, nurses, medical educators, students and other healthcare providers.

Course Objectives:

At the end of the session, participants will be able to:

1. Identify genetic cancer predisposition in women cancer
2. Demonstrate an understanding of the use of next gene sequencing in the treatment of women cancer
3. Identify pathway to personalized care in women cancer

Accreditation and Credit Designation Statements:

QCHP Accreditation Statement:

Weill Cornell Medicine-Qatar is accredited as a provider of Continuing Medical Education (CME) and Continuing Professional Development (CPD) by the Qatar Council for Healthcare Practitioners (QCHP) of the Ministry of Public Health.

This activity is an Accredited Group Learning Activity (Category 1) as defined by the Qatar Council for Healthcare Practitioners-Accreditation Department and is approved for a maximum of 1 hour.

ACCME Accreditation Statement:

The Weill Cornell Medicine-Qatar is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Weill Cornell Medicine-Qatar designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosure: It is the policy of Weill Cornell Medicine-Qatar to adhere to Qatar Council for Healthcare Practitioners (QCHP) and Accreditation Council for Continuing Medical Education (ACCME) Criteria, Policies, and Standards for Commercial Support and content validation in order to ensure fair balance, independence, objectivity, and scientific rigor in all its sponsored programs. All faculty participating in sponsored programs are expected to disclose relevant financial relationships pertaining to their contribution to the activity, and any discussions of off-label or investigational uses of approved commercial products or devices, or of any products or devices not yet approved in the United States and elsewhere. WCM-Q CME activities are intended to be evidence-based and free of commercial bias.

Speaker: Jeremie Arash Rafii Tabrizi, MD has *nothing to disclose and WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.*

Course Director/Planning Committee: Thurayya Arayssi, MD; Planning Committee: Aicha Hind Rifai, MD; Sohaila Cheema, MBBS; Sheila Qureshi, PhD; Therese Lanigan, MSc; Maria Paiva, BSP; Deema Al-Sheikhly, MRes, MEHP, Christopher R. Trigg, PhD, Thomas Hogan, BSc, DDS, Mary Parrott, RRN, MA – have nothing to disclose

Planning Committee: Stephen L. Atkin, MBBS has disclosed the following: Educational Lectures with Novo Nordisk

Coordinator: Laudy Mattar MMJ; Mariette D'Souza have nothing to disclose

CPD Staff: Have nothing to disclose

WCM-Q does not accept industry support for any regularly scheduled series. Any exceptions to this are approved by the CPD Oversight Committee, and will be disclosed prior to this presentation.

To be eligible to receive a certificate:

1. Sign-in at the beginning of each session.
2. Complete the evaluation form that is sent out after the lecture.